Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines

Vaccine

Volumn 12, Issue 8, 1994, Pages 675-681

  Sugimoto, Masanobu ^a   Yamanouchi, Kazuya ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE   (Japan)

Author keywords

attenuated Lister strain; LC16m0; recombinant vaccinia virus; Vaccinia virus

Indexed keywords

LIVE VACCINE; RECOMBINANT VACCINE;

GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT;

HEPATITIS B VACCINES; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; LEUKEMIA VIRUS, BOVINE; RINDERPEST VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0028318440     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)90215-1     Document Type: Review

References (38)

1. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus
2. Vaccinia virus: a selectable eukaryotic cloning and expression vector
3. Large-scale eradication of rabies using recombinant vaccinia—rabies vaccine
4. Recombinant vaccinia virus vaccines
5. Office International de Epizooties
6. Properties of attenuated mutants of vaccinia virus
7. Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8 and their Lister original (LO) strains
8. Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8 Production of intermediate variants by homologous recombination
9. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins
10. The complete DNA sequence of vaccinia virus
11. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence
12. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CV1-78)
13. Die intrakutane Pockenimpfung mit einem schwach virulenten Vaksinia-virus (‘MVA-Virus’)
14. Fowlpox virus as a vector in non-avian species
15. Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain
16. Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen
17. Stability of recombinant vaccinia virus LC16m0 or LC16m8: Preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene
18. Effect of the recombinant vaccinia viruses that express HTLV-1 envelope gene on HTLV-1 infection
19. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type 1 envelope gene
20. Nucleotide sequence of the vaccinia virus hemagglutinin gene
21. Development of heat-stable recombinant rinderpest vaccine
22. Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin
23. Immunization of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus
24. Immunogenicity of a recombinant vaccinia virus expressing envelope glycoprotein of bovine leukaemia virus
25. Induction of neutralizing antibodies against bovine leukosis virus in rabbits by vaccination with recombinant vaccinia virus expressing bovine leukosis virus envelope glycoprotein
26. Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with a vaccinia virus—BLV env recombinant: association with cell-mediated immunity
27. Augmentation of bovine leukemia virus (BLV)-specific lymphocyte proliferation responses in ruminants by inoculation with BLV env—recombinant vaccinia virus: their role in the suppression of BLV replication
28. Involvement of CD8+ T cells in delayed-type hypersensitivity responses against bovine leukemia virus (BLV) induced in sheep vaccinated with recombinant vaccinia virus expressing BLV envelope glycoprotein
29. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51–70
30. A strategy for prophylactic vaccination against HIV
31. Cell-mediated immunity to BLV replication: analogous to HIV immunopathogenesis?
32. Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection
33. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express pre-M and E glycoproteins of Japanese encephalitis virus
34. Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study
35. Transcription mapping of glycoprotein l (gpl) and gpIV of varicella—zoster virus and immunological analysis of the gpl produced in cells infected with the recombinant vaccinia virus
36. A poxvirus derived vector that directs high levels of expression cloned genes in mammalian cells
37. Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses
38. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype